- Stephens Fall Investment Conference & Piper Jaffray Healthcare
Conference -
WALTHAM, Mass.--(BUSINESS WIRE)--
Repligen Corporation (NASDAQ:RGEN) today announced that Walter C.
Herlihy, Ph.D., President and Chief Executive Officer, will be
presenting at two investor conferences in November. Dr. Herlihy will
first participate in the Stephens Fall Investment Conference on November
14, and will later present at the Piper Jaffray 24th Annual
Healthcare Conference on November 27. Both conferences will take place
at The New York Palace Hotel. At each, Dr. Herlihy will provide a
corporate update and address questions from the audience.
Repligen’s presentation at the Piper Jaffray Annual Healthcare
Conference will be webcast and made available live through the Investors
section of Company’s website at www.repligen.com.
This presentation is currently scheduled to begin on Tuesday, November
27 at 8:50 a.m. EST. To access the live webcast, please log on
approximately 15 minutes prior to the scheduled start time. The webcast
will also be archived for a period of time on the Company’s website.
About Repligen Corporation
Repligen Corporation is a life sciences company focused on the
development, production and commercialization of high-value consumable
products used in the process of manufacturing biological drugs. Our
bioprocessing products are sold to major life sciences and
biopharmaceutical companies worldwide. We are a leading manufacturer of
Protein A, a critical reagent used during the production of monoclonal
antibody therapeutics. We also supply several growth factor products
used to increase cell culture productivity during fermentation. In the
burgeoning area of disposable biomanufacturing technologies, we have
developed and market a series of OPUS®(Open Platform User
Specified) pre-packed chromatography columns for use in clinical-stage
and/or niche biologics manufacturing. In addition to our core
bioprocessing business, we have a portfolio of clinical-stage partnering
assets, including our pancreatic imaging agent in Phase 3 development
and two central nervous system orphan drug candidates. Repligen’s
corporate headquarters are located in Waltham, MA, USA; we have an
additional manufacturing facility in Lund, Sweden. For more information,
please visit our website at www.repligen.com.
This press release may contain forward-looking statements within the
meaning of the federal securities laws. Investors are cautioned that
statements in this press release which are not strictly historical
statements including, without limitation, statements identified by words
like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could”
and similar expressions, constitute forward-looking statements. Such
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially from
those anticipated, including, risks discussed from time to time in our
filings with the Securities and Exchange Commission. We expressly
disclaim any responsibility to update forward-looking statements, except
as required by law.
Repligen Corporation
Sondra S. Newman, 781-419-1881
Director
Investor Relations
snewman@repligen.com
Source: Repligen Corporation